Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA.
Cancer Risk Assessment and Clinical Cancer Genetics, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; Cancer Risk Assessment and Clinical Cancer Genetics, Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Urol Clin North Am. 2021 Aug;48(3):311-322. doi: 10.1016/j.ucl.2021.03.003. Epub 2021 Jun 12.
Germline testing for prostate cancer (PCA) is revolutionizing PCA care. Two PARP inhibitors are FDA approved for men with metastatic, castration-resistant disease after progression on first-line therapies. In the screening setting, genetic test results may inform initiation and screening strategies. For men with early-stage disease, literature is emerging on the possible role of germline testing in active surveillance discussions. As such, urologists and oncologists must gain working knowledge of the principles and practice of germline testing and hereditary cancer implications for responsible implementation. Here the authors outline key learning areas and practice strategies for responsible dissemination of PCA germline testing.
前列腺癌（PCA）的种系检测正在彻底改变 PCA 的治疗方式。两种 PARP 抑制剂已获得美国食品和药物管理局（FDA）的批准，用于一线治疗后进展为转移性、去势抵抗性疾病的男性。在筛查环境中，遗传检测结果可能为起始和筛查策略提供信息。对于早期疾病患者，有关种系检测在主动监测讨论中可能发挥作用的文献正在涌现。因此，泌尿科医生和肿瘤学家必须掌握种系检测的原则和实践以及遗传性癌症对负责任实施的影响方面的相关知识。在此，作者概述了 PCA 种系检测的负责任传播的关键学习领域和实践策略。
